116 related articles for article (PubMed ID: 36343786)
1. UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.
Lacombe L; Hovington H; Brisson H; Mehdi S; Beillevaire D; Émond JP; Wagner A; Villeneuve L; Simonyan D; Ouellet V; Barrès V; Latour M; Aprikian A; Bergeron A; Castonguay V; Couture F; Chevalier S; Brimo F; Fazli L; Fleshner N; Gleave M; Karakiewicz PI; Lattouf JB; Trudel D; van der Kwast T; Mes-Masson AM; Pouliot F; Fradet Y; Audet-Walsh E; Saad F; Guillemette C; Lévesque E
Cancer Lett; 2023 Jan; 553():215994. PubMed ID: 36343786
[TBL] [Abstract][Full Text] [Related]
2. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.
Lin HP; Ho HM; Chang CW; Yeh SD; Su YW; Tan TH; Lin WJ
FASEB J; 2019 Dec; 33(12):14653-14667. PubMed ID: 31693867
[TBL] [Abstract][Full Text] [Related]
3. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients.
Ravindran A; Krieger KL; Kaushik AK; Hovington H; Mehdi S; Piyarathna DWB; Putluri V; Basil P; Rasaily U; Gu F; Dang T; Choi JM; Sonavane R; Jung SY; Wang L; Mehra R; Weigel NL; Putluri N; Rowley DR; Palapattu GS; Guillemette C; Lacombe L; Lévesque É; Sreekumar A
Cells; 2022 Jul; 11(15):. PubMed ID: 35954173
[TBL] [Abstract][Full Text] [Related]
4. The long non-coding RNA PCAL7 promotes prostate cancer by strengthening androgen receptor signaling.
Li Z; Teng J; Jia Z; Zhang G; Ai X
J Clin Lab Anal; 2021 Feb; 35(2):e23645. PubMed ID: 33219721
[TBL] [Abstract][Full Text] [Related]
5. The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.
Mandel A; Larsson P; Sarwar M; Semenas J; Syed Khaja AS; Persson JL
Mol Med; 2018 Jun; 24(1):34. PubMed ID: 30134822
[TBL] [Abstract][Full Text] [Related]
6. A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer.
Shi Z; Chen J; Wumaner A; Li M; Liang C; Li M
Biochem Biophys Res Commun; 2021 Jan; 537():78-84. PubMed ID: 33387886
[TBL] [Abstract][Full Text] [Related]
7. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.
Belledant A; Hovington H; Garcia L; Caron P; Brisson H; Villeneuve L; Simonyan D; Têtu B; Fradet Y; Lacombe L; Guillemette C; Lévesque E
Eur Urol; 2016 Apr; 69(4):601-609. PubMed ID: 26215610
[TBL] [Abstract][Full Text] [Related]
8. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
[TBL] [Abstract][Full Text] [Related]
9. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
[TBL] [Abstract][Full Text] [Related]
10. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.
Cai C; Portnoy DC; Wang H; Jiang X; Chen S; Balk SP
Cancer Res; 2009 Jun; 69(12):5202-9. PubMed ID: 19491261
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
13. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
14. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
15. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
18. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
19. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
20. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.
Hu Y; Sun H; Owens RT; Wu J; Chen YQ; Berquin IM; Perry D; O'Flaherty JT; Edwards IJ
Neoplasia; 2009 Oct; 11(10):1042-53. PubMed ID: 19794963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
